Literature DB >> 19502791

Constitutive non-canonical NFkappaB signaling in pancreatic cancer cells.

Catherine E Wharry1, Kathleen M Haines, Richard G Carroll, Michael J May.   

Abstract

Constitutive classical NFkappaB activation has been implicated in the development of pancreatic cancer, and inhibition of classical NFkappaB signaling sensitizes pancreatic cancer cells to apoptosis. However, the role of the more recently described non-canonical NFkappaB pathway has not been specifically addressed in pancreatic cancer. The non-canonical pathway requires stabilization of NIK and IKKalpha-dependent phosphorylation and processing of NFkappaB2/p100 to p52. This leads to the activation of p52-RelB heterodimers that regulate genes encoding lymphoid-specific chemokines and cytokines. We performed qRT-PCR to detect gene expression in a panel of pancreatic ductal adenocarcinoma cell lines (BxPC-3, PCA-2, PANC-1, Capan-1, Hs-766T, AsPC-1, MiaPACA-2) and found only modest elevation of classical NFkappaB-dependent genes. In contrast, each of the tumor cell lines displayed dramatically elevated levels of subsets of the non-canonical NFkappaB target genes CCL19, CCL21, CXCL12, CXCL13 and BAFF. Consistent with activation of the non-canonical pathway, p52 and RelB co-localized in adenocarcinoma cells in sections of pancreatic tumor tissue, and each of the tumor cell lines displayed elevated p52 levels. Furthermore, p52 and RelB co-immunoprecipitated from pancreatic cancer cells and immunoblotting revealed that NIK was stabilized and p100 was constitutively phosphorylated in a subset of the cell lines. Finally, stable overexpression of dominant negative IKKalpha significantly inhibited non-canonical target gene expression in BxPC-3 cells. These findings therefore demonstrate that the non-canonical NFkappaB pathway is constitutively active and functional in pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19502791      PMCID: PMC2910422          DOI: 10.4161/cbt.8.16.8961

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  55 in total

Review 1.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 2.  The two NF-kappaB activation pathways and their role in innate and adaptive immunity.

Authors:  Giuseppina Bonizzi; Michael Karin
Journal:  Trends Immunol       Date:  2004-06       Impact factor: 16.687

3.  Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells.

Authors:  E Dejardin; G Bonizzi; A Bellahcène; V Castronovo; M P Merville; V Bours
Journal:  Oncogene       Date:  1995-11-02       Impact factor: 9.867

4.  Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.

Authors:  Bing He; Amy Chadburn; Erin Jou; Elaine J Schattner; Daniel M Knowles; Andrea Cerutti
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

5.  Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells.

Authors:  Jiangong Niu; Zhongkui Li; Bailu Peng; Paul J Chiao
Journal:  J Biol Chem       Date:  2003-12-16       Impact factor: 5.157

6.  Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma.

Authors:  Akira Fujii; Koichi Ohshima; Makoto Hamasaki; Yoshifumi Makimoto; Seiji Haraoka; Hidetsuna Utsunomiya; Masatoshi Okazaki; Masahiro Kikuchi
Journal:  Int J Oncol       Date:  2004-03       Impact factor: 5.650

7.  NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells.

Authors:  Henry Q Xiong; James L Abbruzzese; Edward Lin; Liwei Wang; Leizhen Zheng; Keping Xie
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

8.  Increased expression of NF-kappa B subunits in human pancreatic cancer cells.

Authors:  Nicole M Chandler; Jonathan J Canete; Mark P Callery
Journal:  J Surg Res       Date:  2004-05-01       Impact factor: 2.192

9.  SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation.

Authors:  Yong Xu; Fang Fang; Daret K St Clair; Pradoldej Sompol; Sajni Josson; William H St Clair
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

10.  CXCL13 production by an established lymph node stromal cell line via lymphotoxin-beta receptor engagement involves the cooperation of multiple signaling pathways.

Authors:  Hidenori Suto; Tomoya Katakai; Manabu Sugai; Tatsuo Kinashi; Akira Shimizu
Journal:  Int Immunol       Date:  2009-02-27       Impact factor: 4.823

View more
  39 in total

Review 1.  RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells.

Authors:  Aaron K Holley; Yong Xu; Daret K St Clair; William H St Clair
Journal:  Ann N Y Acad Sci       Date:  2010-07       Impact factor: 5.691

2.  Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk.

Authors:  Courey Averett; Arun Bhardwaj; Sumit Arora; Sanjeev K Srivastava; Mohammad Aslam Khan; Aamir Ahmad; Seema Singh; James E Carter; Moh'd Khushman; Ajay P Singh
Journal:  Carcinogenesis       Date:  2016-11-01       Impact factor: 4.944

3.  Molecular predictors of gemcitabine response in pancreatic cancer.

Authors:  Ioannis A Voutsadakis
Journal:  World J Gastrointest Oncol       Date:  2011-11-15

4.  GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.

Authors:  Deepali Bang; Willie Wilson; Meagan Ryan; Jen Jen Yeh; Albert S Baldwin
Journal:  Cancer Discov       Date:  2013-04-01       Impact factor: 39.397

Review 5.  Anti-cancer IAP antagonists promote bone metastasis: a cautionary tale.

Authors:  Chang Yang; Deborah Veis Novack
Journal:  J Bone Miner Metab       Date:  2013-06-06       Impact factor: 2.626

Review 6.  Inhibitory kappa B Kinases as targets for pharmacological regulation.

Authors:  Carly Gamble; Kathryn McIntosh; Rebecca Scott; Ka Ho Ho; Robin Plevin; Andrew Paul
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

7.  Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?

Authors:  Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2013-05       Impact factor: 4.512

8.  CXCL13 Signaling in the Tumor Microenvironment.

Authors:  Muzammal Hussain; Jinsong Liu; Gui-Zhen Wang; Guang-Biao Zhou
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.

Authors:  G M De Donatis; E Le Pape; A Pierron; Y Cheli; V Hofman; P Hofman; M Allegra; K Zahaf; P Bahadoran; S Rocchi; C Bertolotto; R Ballotti; T Passeron
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

10.  B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation.

Authors:  Sumit Bhattacharyya; Alip Borthakur; Sangeeta Tyagi; Ravinder Gill; Mei Ling Chen; Pradeep K Dudeja; Joanne K Tobacman
Journal:  J Biol Chem       Date:  2009-11-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.